Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE plus sorafenib with or without camrelizumab in advanced liver cancer
ChiCTR2200058703Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hepatocellular carcinoma (HCC) comparing DEB-TACE + sorafenib + camrelizumab with DEB-TACE + sorafenib (2 arms). Planned start Apr 2022; status: not yet recruiting.
02
Drugs
camrelizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200058703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058703.